Ultimovacs announces Acceptance of Publication in ‘Frontiers in Immunology’ featuring positive results from Phase I trial evaluating UV1 in Non-Small Cell Lung Cancer
Oslo, 2 November 2020: Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), today announced the acceptance of publication in Frontiers in Immunology, outlining the positive long-term follow-up data from the company’s Phase I trial evaluating its proprietary universal cancer vaccine, UV1, in non-small cell lung cancer. The publication will cover detailed outcomes of the study for the 18 patients receiving UV1 monotherapy as maintenance treatment.

“Today’s acceptance of publication in Frontiers in Immunology supports our goal to raise UV1 awareness among the scientific and medical communities through publications and presentations at medical conferences,” stated Carlos de Sousa, Chief Executive Officer at Ultimovacs. “Continued positive signs of safety and tolerability are of great importance for us as we are currently evaluating UV1 in triple combinations in two Phase II studies and safety remains our primary focus as we develop treatments for patients in need.”